The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease

Translational Research

Volumn 179, Issue , 2017, Pages 126-138

  Ochoa Repáraz, Javier ^a   Kasper, Lloyd H ^b  

^a EASTERN WASHINGTON UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD39 ANTIGEN; APYRASE; LEUKOCYTE ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTESTINE FLORA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; GASTROINTESTINAL TRACT; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD; APYRASE; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; T-LYMPHOCYTES, REGULATORY;

EID: 85006257472     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.07.016     Document Type: Review

References (100)

1. 1 Dendrou, C.A., Fugger, L., Friese, M.A., Immunopathology of multiple sclerosis. Nature 15 (2015), 545–558.
2. 2 Compston, A., Coles, A., Multiple sclerosis. Lancet 372 (2008), 1502–1517.
3. 3 Sawcer, S., The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 131 (2008), 3118–3131.
4. 4 Dendrou, C.A., Plagnol, V., Fung, E., et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 41 (2009), 1011–1015.
5. 5 Gregory, S.G., Schmidt, S., Seth, P., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39 (2007), 1083–1091.
6. 6 Gourraud, P.A., Harbo, H.F., Hauser, S.L., Baranzini, S.E., The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 248 (2012), 87–103.
7. 7 Consortium TIMSGCTWTCC. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 (2011), 214–219.
8. 8 Hauser, S.L., The Charcot Lecture | beating MS: a story of B cells, with twists and turns. Mult Scler 21 (2015), 8–21.
9. 9 Ochoa-Repáraz, J., Kasper, L.H., Gut microbiome and the risk factors in central nervous system autoimmunity. FEBS Lett 588 (2014), 4214–4222.
10. 10 Mandia, D., Ferraro, O., Nosari, G., Montomoli, C., Zardini, E., Bergamaschi, R., Environmental factors and multiple sclerosis severity: a descriptive study. Int J Environ Res Public Health 11 (2014), 6417–6432.
11. 11 Lincoln, J.A., Cook, S.D., An overview of gene-epigenetic-environmental contributions to MS causation. J Neurol Sci 286 (2009), 54–57.
12. 12 Josefowicz, S.Z., Rudensky, A., Control of regulatory T cell lineage commitment and maintenance. Immunity 30 (2009), 616–625.
13. 13 Crampton, S.P., Voynova, E., Bolland, S., Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci 1183 (2010), 58–68.
14. 14 Matsushita, T., Yanaba, K., Bouaziz, J.D., Fujimoto, M., Tedder, T.F., Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118 (2008), 3420–3430.
15. 15 Longbrake, E.E., Cross, A.H., Effect of multiple sclerosis disease-modifying therapies on B cells and humoral immunity. JAMA Neurol 73 (2016), 219–225.
16. 16 Sundstedt, A., O'Neill, E.J., Nicolson, K.S., Wraith, D.C., Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 170 (2003), 1240–1248.
17. 17 Weiner, H.L., Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 3 (2001), 947–954.
18. 18 Faria, A.M., Weiner, H.L., Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 13 (2006), 143–157.
19. 19 Nowak, M., Stein-Streilein, J., Invariant NKT cells and tolerance. Int Rev Immunol 26 (2007), 95–119.
20. 20 Perdigoto, A.L., Chatenoud, L., Bluestone, J.A., Herold, K.C., Inducing and administering tregs to treat human disease. Front Immunol, 6, 2015, 654.
21. 21 Viglietta, V., Baecher-Allan, C., Weiner, H.L., Hafler, D.A., Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004), 971–979.
22. 22 Haas, J., Hug, A., Viehöver, A., et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 35 (2005), 3343–3352.
23. 23 Huan, J., Culbertson, N., Spencer, L., et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 8 (2005), 45–52.
24. 24 Venken, K., Hellings, N., Hensen, K., et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 83 (2006), 1432–1446.
25. 25 Feger, U., Luther, C., Poeschel, S., Melms, A., Tolosa, E., Wiendl, H., Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 147 (2007), 412–418.
26. 26 Fletcher, J.M., Lonergan, R., Costelloe, L., et al. CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 183 (2009), 7602–7610.
27. 27 Mueller, N.T., Bakacs, E., Combellick, J., Grigoryan, Z., Dominguez-Bello, M.G., The infant microbiome development: mom matters. Trends Mol Med 21 (2015), 109–117.
28. 28 Ege, M.J., Mayer, M., Normand, A.C., et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 364 (2011), 701–709.
29. 29 David, L.A., Maurice, C.F., Carmody, R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2013), 559–563.
30. 30 Cani, P.D., Bibiloni, R., Knauf, C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481.
31. 31 Nouri, M., Bredberg, A., Weström, B., Lavasani, S., Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells. PLoS One, 9, 2014, e106335.
32. 32 Hsiao, E.Y., McBride, S.W., Hsien, S., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155 (2013), 1451–1463.
33. 33 Kozakova, H., Schwarzer, M., Tuckova, L., et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol 13 (2015), 251–262.
34. 34 Stappenbeck, T.S., Hooper, L.V., Gordon, J.I., Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 99 (2002), 15451–15455.
35. 35 Ezendam, J., de Klerk, A., Gremmer, E.R., van Loveren, H., Effects of Bifidobacterium animalis administered during lactation on allergic and autoimmune responses in rodents. Clin Exp Immunol 154 (2008), 424–431.
36. 36 Ochoa-Repáraz, J., Mielcarz, D.W., Wang, Y., et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 3 (2010), 487–495.
37. 37 Wang, Y., Begum-Haque, S., Telesford, K.M., et al. A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes 5 (2014), 552–561.
38. 38 Wang, Y., Telesford, K.M., Ochoa-Reparaz, J., et al. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling. Nat Commun, 5, 2014, 4432.
39. 39 de Vries, H.E., Kooij, G., Frenkel, D., Georgopoulos, S., Monsonego, A., Janigro, D., Inflammatory events at blood–brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia 53 Suppl 6 (2012), 45–52.
40. 40 Ransohoff, R.M., Engelhardt, B., The anatomical and cellular basis of immune surveillance in the central nervous system. Nature 12 (2012), 623–635.
41. 41 Louveau, A., Smirnov, I., Keyes, T.J., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
42. 42 Byrne, C.S., Chambers, E.S., Morrison, D.J., Frost, G., The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes 39 (2015), 1331–1338.
43. 43 Braniste, V., Al-Asmakh, M., Kowal, C., et al. The gut microbiota influences blood–brain barrier permeability in mice. Sci Transl Med, 6, 2014, 263ra158.
44. 44 Mariadason, J.M., Barkla, D.H., Gibson, P.R., Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol 272 (1997), G705–G712.
45. 45 Peng, L., He, Z., Chen, W., Holzman, I.R., Lin, J., Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61 (2007), 37–41.
46. 46 Mariadason, J.M., Catto-Smith, A., Gibson, P.R., Modulation of distal colonic epithelial barrier function by dietary fibre in normal rats. Gut 44 (1999), 394–399.
47. 47 Cani, P.D., Possemiers, S., Van de Wiele, T., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58 (2009), 1091–1103.
48. 48 Macfabe, D.F., Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis, 23, 2012, 1.
49. 49 Conn, A.R., Fell, D.I., Steele, R.D., Characterization of alpha-keto acid transport across blood–brain barrier in rats. Am J Physiol 245 (1983), E253–E260.
50. 50 Michel, L., Prat, A., One more role for the gut: microbiota and blood brain barrier. Ann Transl Med, 4, 2016, 15.
51. 51 Kamada, N., Chen, G.Y., Inohara, N., Núñez, G., Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14 (2013), 685–690.
52. 52 Mayer, E.A., Knight, R., Mazmanian, S.K., Cryan, J.F., Tillisch, K., Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 34 (2014), 15490–15496.
53. 53 Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9 (2009), 313–323.
54. 54 Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., Kasper, D.L., An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122 (2005), 107–118.
55. 55 Ochoa-Reparaz, J., Kasper, L.H., The second brain: is the gut microbiota a link between obesity and central nervous system disorders?. Curr Obes Rep 5 (2016), 51–64.
56. 56 Bach, J.F., The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 (2002), 911–920.
57. 57 Joscelyn, J., Kasper, L.H., Digesting the emerging role for the gut microbiome in central nervous system demyelination. Mult Scler 20 (2014), 1553–1559.
58. 58 Lee, Y.K., Menezes, J.S., Umesaki, Y., Mazmanian, S.K., Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 108 Suppl 1 (2011), 4615–4622.
59. 59 Wu, H.J., Ivanov, I.I., Darce, J., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32 (2010), 815–827.
60. 60 Chappert, P., Role of SFB in autoimmune arthritis: an example of regulation of autoreactive T cell sensitivity in the gut. Gut Microbes 5 (2014), 259–264.
61. 61 Shapira, L., Ayalon, S., Brenner, T., Effects of Porphyromonas gingivalis on the central nervous system: activation of glial cells and exacerbation of experimental autoimmune encephalomyelitis. J Periodontol 73 (2002), 511–516.
62. 62 Nichols, F.C., Housley, W.J., O'Conor, C.A., Manning, T., Wu, S., Clark, R.B., Unique lipids from a common human bacterium represent a new class of Toll-like receptor 2 ligands capable of enhancing autoimmunity. Am J Pathol 175 (2009), 2430–2438.
63. 63 Lavasani, S., Dzhambazov, B., Nouri, M., et al. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS One 5 (2010), e9009–e9011.
64. 64 Berer, K., Mues, M., Koutrolos, M., et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479 (2011), 538–541.
65. 65 Ochoa-Repáraz, J., Mielcarz, D.W., Ditrio, L.E., et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 183 (2009), 6041–6050.
66. 66 Yokote, H., Miyake, S., Croxford, J.L., Oki, S., Mizusawa, H., Yamamura, T., NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 173 (2008), 1714–1723.
67. 67 Ochoa-Repáraz, J., Mielcarz, D.W., Ditrio, L.E., et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide a expression. J Immunol 185 (2010), 4101–4108.
68. 68 Takata, K., Kinoshita, M., Okuno, T., et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. PLoS One, 6, 2011, e27644.
69. 69 Rezende, R.M., Oliveira, R.P., Medeiros, S.R., et al. Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J Autoimmun 40 (2013), 45–57.
70. 70 Wang, Q., McLoughlin, R.M., Cobb, B.A., et al. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 203 (2006), 2853–2863.
71. 71 Round, J.L., Mazmanian, S.K., Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107 (2009), 12204–12209.
72. 72 Mazmanian, S.K., Round, J.L., Kasper, D.L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453 (2008), 620–625.
73. 73 Dasgupta, S., Erturk-Hasdemir, D., Ochoa-Reparaz, J., Reinecker, H.C., Kasper, D.L., Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 15 (2014), 413–423.
74. 74 Johnson, J.L., Jones, M.B., Cobb, B.A., Bacterial capsular polysaccharide prevents the onset of asthma through T-cell activation. Glycobiology 25 (2015), 368–375.
75. 75 Cobb, B.A., Kasper, D.L., Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology 18 (2008), 707–718.
76. 76 Cobb, B.A., Kasper, D.L., Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens. Cell Microbiol 7 (2005), 1398–1403.
77. 77 Antonioli, L., Pacher, P., Vizi, E.S., Haskó, G., CD39 and CD73 in immunity and inflammation. Trends Mol Med 19 (2013), 355–367.
78. 78 Kochetkova, I., Golden, S., Holderness, K., Callis, G., Pascual, D.W., IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 184 (2010), 7144–7153.
79. 79 Kochetkova, I., Thornburg, T., Callis, G., Holderness, K., Maddaloni, M., Pascual, D.W., Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. J Immunol 192 (2014), 804–816.
80. 80 Kochetkova, I., Thornburg, T., Callis, G., Pascual, D.W., Segregated regulatory CD39+CD4+ T cell function: TGF- -producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol 187 (2011), 4654–4666.
81. 81 Maddaloni, M., Kochetkova, I., Jun, S., Callis, G., Thornburg, T., Pascual, D.W., Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-β-producing CD39+ regulatory T cells. PLoS One, 10, 2015, e0117825.
82. 82 Ochoa-Repáraz, J., Riccardi, C., Rynda, A., Jun, S., Callis, G., Pascual, D.W., Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J Immunol 178 (2007), 1791–1799.
83. 83 Thiolat, A., Semerano, L., Pers, Y.M., et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 66 (2014), 273–283.
84. 84 Peres, R.S., Liew, F.Y., Talbot, J., et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc Natl Acad Sci U S A 112 (2015), 2509–2514.
85. 85 Asnagli, H., Martire, D., Belmonte, N., et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther, 16, 2014, R11.
86. 86 Longhi, M.S., Moss, A., Bai, A., et al. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One, 9, 2014, e87956.
87. 87 Bai, A., Moss, A., Kokkotou, E., et al. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol 193 (2014), 3366–3377.
88. 88 Chia, J.S., McRae, J.L., Thomas, H.E., et al. The protective effects of CD39 overexpression in multiple low-dose streptozotocin-induced diabetes in mice. Diabetes 62 (2013), 2026–2035.
89. 89 Jangi, S., Gandhi, R., Cox, L.M., et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun, 7, 2016, 12015.
90. 90 Miyake, S., Kim, S., Suda, W., et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters. PLoS One, 10, 2015, e0137429.
91. 91 Farrokhi, V., Nemati, R., Nichols, F.C., et al. Bacterial lipodipeptide, lipid 654, is a microbiome-associated biomarker for multiple sclerosis. Clin Transl Immunology, 2, 2013, e8.
92. 92 Cantarel, B.L., Waubant, E., Chehoud, C., et al. Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med 63 (2015), 729–734.
93. 93 Ochoa-Repáraz, J., Colpitts, S., Kasper, E., keever, A., Liljenberg, C., Kasper, L., The gut microbiome affects the progression of disease in a murine model of secondary progressive MS. Neurology, 86 Suppl 16, 2016, P5.324.
94. 94 Atarashi, K., Tanoue, T., Shima, T., et al. Induction of colonic regulatory T cells by indigenous clostridium species. Science 331 (2011), 337–341.
95. 95 Grant, C.R., Liberal, R., Holder, B.S., et al. Dysfunctional CD39 POSregulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis. Hepatology 59 (2014), 1007–1015.
96. 96 Telesford, K.M., Yan, W., Ochoa-Reparaz, J., et al. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39(+)Foxp3(+) T cells and Treg function. Gut Microbes 6 (2015), 234–242.
97. 97 Muls, N., Dang, H.A., Sindic, C.J., van Pesch, V., Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients. PLoS One, 9, 2014, e113025.
98. 98 Mielcarz, D., Bergeron, A., DeLong, J., et al. Anti-CD52 therapy induces significant changes in T and B cell subset frequency and cytokine expression by B cells in multiple sclerosis patients. Mult Scler 19 Suppl 1 (2013), 74–558.
99. 99 Pant, A., Wang, Y., Mielcarz, D.W., et al. Anti-mu CD52 treatment induces CD39+ regulatory cells in the GALT and suppresses inflammatory cytokine expression within the CNS of EAE mice. Mult Scler, 21 Suppl 11, 2015, 244.
100. 100 Kircher, C., Kasper, E., Telesford, K.M., et al. A novel mechanism of action for teriflunomide by the induction of immunosuppressive gut CD39+FoxP3+Tregs in mice. Mult Scler, 21 Suppl 11, 2015, 546.